Aldeyra Therapeutics (ALDX) Return on Capital Employed (2014 - 2026)
Aldeyra Therapeutics (ALDX) posted Return on Capital Employed of 63.15% for Q1 2026, up 15.61% on a QoQ basis from 74.84% in Q4 2025, and up 911.0% year-over-year from 6.25% in Q1 2025.
Aldeyra Therapeutics (ALDX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Aldeyra Therapeutics' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 63.15% for Q1 2026.
- Quarterly Return on Capital Employed rose 911.0% year-over-year to 63.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.15% (up 911.0% YoY) and the FY2025 annual result came in at 58.27%, down 253.0% from the prior year.
- Return on Capital Employed was 63.15% for Q1 2026 at Aldeyra Therapeutics, up from 74.84% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.74% in Q1 2024 and bottomed at 89.53% in Q2 2025.
- A 5-year average of 50.27% and a median of 39.69% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 1095 bps — and 2025, when it slumped 4894 bps.
- Aldeyra Therapeutics' Return on Capital Employed stood at 36.84% in 2022, then gained by 7 bps to 34.09% in 2023, then plunged by 91 bps to 65.09% in 2024, then declined by 15 bps to 74.84% in 2025, then advanced by 16 bps to 63.15% in 2026.
- Business Quant data shows ALDX's Return on Capital Employed at 63.15% in Q1 2026, 74.84% in Q4 2025, and 85.4% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | -63.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.15% |
| Dec 31, 2025 | -74.84% |
| Sep 30, 2025 | -85.40% |
| Jun 30, 2025 | -89.53% |
| Mar 31, 2025 | -72.27% |
| Dec 31, 2024 | -65.09% |
| Sep 30, 2024 | -47.49% |
| Jun 30, 2024 | -40.58% |
| Mar 31, 2024 | -28.74% |
| Dec 31, 2023 | -34.09% |
| Sep 30, 2023 | -38.81% |
| Jun 30, 2023 | -38.02% |
| Mar 31, 2023 | -39.69% |
| Dec 31, 2022 | -36.84% |
| Sep 30, 2022 | -37.62% |
| Jun 30, 2022 | -33.25% |
| Mar 31, 2022 | -29.25% |
| Dec 31, 2021 | -24.61% |
| Sep 30, 2021 | -21.72% |
| Jun 30, 2021 | -23.17% |